The bill creates a federal baseline to reduce toxic chemicals in food contact materials and requires attention to vulnerable populations—improving health protections in the long run—while imposing compliance costs on industry, delaying immediate effect for two years, and leaving risks from untested substitutes and legal disputes to be managed.
Consumers—especially children, pregnant people, and seniors—will face reduced exposure to several listed toxic chemicals in food contact materials beginning two years after enactment.
FDA must evaluate harms to vulnerable groups when reviewing substitute substances, improving the chance that replacements are safer for infants, pregnant people, and exposed workers.
Establishes a federal minimum health-protection standard for food contact chemicals while explicitly allowing states and localities to adopt stronger protections.
Manufacturers and food-packaging suppliers (including many small businesses) will likely incur compliance, reformulation, and substitution costs that could raise retail prices.
The two-year delay before the rule takes effect will prolong ongoing consumer exposures to the listed chemicals, extending risk for children and pregnant people.
If substitute chemicals are approved without complete safety data, vulnerable populations (infants, pregnant people, exposed workers) could still suffer harms from replacement substances.
Based on analysis of 2 sections of legislative text.
Designates a list of chemicals as "deemed unsafe" for food contact materials and requires FDA to consider vulnerable populations when reviewing alternatives.
Official title: Amend the Federal Food, Drug, and Cosmetic Act to deem certain substances to be unsafe for use as food contact substances, and for other purposes.
Introduced June 9, 2026 by Richard Blumenthal · Last progress June 9, 2026
Declares a list of specific chemicals and chemical classes "deemed unsafe" for use in food contact materials and amends the Federal Food, Drug, and Cosmetic Act to bar those substances as food contact substances; requires the FDA to evaluate replacement petitions with consideration of harms to vulnerable populations. The rule establishes a two-year delay before the new standard takes effect and explicitly preserves state and local laws that are equal or more protective.